TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05702853: Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Sponsor: Medical University of South Carolina · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05702853 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05702853 Rescue Dossier →